APO-VERAP TABLET 120MG

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

VERAPAMIL HYDROCHLORIDE

Fáanlegur frá:

APOTEX INC

ATC númer:

C08DA01

INN (Alþjóðlegt nafn):

VERAPAMIL

Skammtar:

120MG

Lyfjaform:

TABLET

Samsetning:

VERAPAMIL HYDROCHLORIDE 120MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

100/500

Gerð lyfseðils:

Prescription

Lækningarsvæði:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Vörulýsing:

Active ingredient group (AIG) number: 0113846001; AHFS:

Leyfisstaða:

MARKETED

Leyfisdagur:

1989-12-31

Vara einkenni

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
APO-VERAP
Verapamil Hydrochloride
Tablets, 80 mg and 120 mg, oral
BP
Antianginal / Antiarrhythmic / Antihypertensive Agent
APOTEX INC.
150 Signet Drive,
Weston, Ontario
M9L 1T9.
Date of Initial Authorization:
JUN 30, 1989
Date of Revision:
MAY 12, 2022
www.apotex.ca/products
Submission Control Number: 258995
_ _
_VERAPAMIL HYDROCHLORIDE TABLETS (verapamil hydrochloride) _
_Page 2 of 48_
RECENT MAJOR LABEL CHANGES
1 Indications, 1.1 Pediatrics
05/2022
1 Indications, 1.2 Geriatrics
05/2022
2 Contraindications
05/2022
4 Dosage and Administration, 4.2 Recommended Dose and
Dosage Adjustment
05/2022
7 Warnings and Precautions, Cardiovascular
05/2022
7 Warnings and Precautions, Hepatic/Biliary/Pancreatic
05/2022
7 Warnings and Precautions, Monitoring and Laboratory tests
05/2022
7 Warnings and Precautions, Neurologic
05/2022
7 Warnings and Precautions, 7.1.1 Pregnant Women
05/2022
7 Warnings and Precautions, 7.1.3 Pediatrics
05/2022
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................5
1
INDICATIONS
................................................................................................................5
1.1
Pediatrics
............................................................................................................5
1.2
Geriatrics.............................................................................................................5
2
CONTRAINDICATIONS
...................................................................................................5
4
DOSAGE AND
ADMINISTRATION..........................................